Authors' contributions JC made substantial contributions to conception and design of the study, acquisition, analysis and interpretation of data, revised the manuscript critically for important intellectual content, and was a major contributor to writing the manuscript
Read the full breakdown: Watch the July 23, 2026 meeting: Watch the July 24, 2026 meeting: Peptide therapy has been one of the most-asked-about topics among our provider partners this year
Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Daily oral semaglutide is not yet licensed for weight loss in the UK at any dose, although at lower doses it is comparably effective to subcutaneous semaglutide for management of hyperglycaemia in type 2 diabetes
Many claims about completely removing stretch marks are misconceptions